Context Therapeutics (NASDAQ:CNTX – Get Free Report) was upgraded by Citizens Jmp to a “strong-buy” rating in a note issued ...

Shares of Context Therapeutics Inc. rose over 7% in Wednesday's pre-market trading after JMP Securities initiated coverage ...

Fintel reports that on January 8, 2025, JMP Securities initiated coverage of Context Therapeutics (NasdaqCM:CNTX) with a ...

Context Therapeutics (CNTX) has received a new Buy rating, initiated by JMP Securities analyst, Silvan Tuerkcan.Stay Ahead of the ...

D. Boral Capital has recently initiated Context Therapeutics Inc (CNTX) stock to Buy rating, as announced on November 25, 2024, according to Finviz. Analyst ratings are significant because they ...

Context Therapeutics has a 12 month low of $0.89 and a 12 month high of $2.75. The company has a market capitalization of $76.50 million, a price-to-earnings ratio of -1.12 and a beta of 2.00.

Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule ...

Piper Sandler has reaffirmed its Overweight rating on shares of Context Therapeutics (NASDAQ: CNTX) with a consistent price target of $4.50. The firm's confidence is bolstered by... Piper Sandler ...

CTIM-76 is under clinical development by Context Therapeutics and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 73% phase transition success ...

About Light Horse Therapeutics Light Horse Therapeutics emerged from the ... systematically interrogates complex signaling pathways in their native, cellular context to uncover unique sites of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...